Jean Jacques Bienaime - Apr 28, 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Apr 28, 2022
Transactions value $
-$1,149,050
Form type
4
Date filed
5/2/2022, 09:27 PM
Previous filing
Apr 20, 2022
Next filing
May 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $749K +20K +5.97% $37.46 355K Apr 28, 2022 Direct F1
transaction BMRN Common Stock Sale -$1.68M -20K -5.63% $83.79 335K Apr 28, 2022 Direct F1
transaction BMRN Common Stock Options Exercise $187K +5K +1.49% $37.46 340K Apr 29, 2022 Direct F2
transaction BMRN Common Stock Sale -$410K -5K -1.47% $81.95 335K Apr 29, 2022 Direct F2
holding BMRN Common Stock 248K Apr 28, 2022 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -20K -36.36% $0.00 35K Apr 28, 2022 Common Stock 20K $37.46 Direct F1, F3
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -5K -14.29% $0.00 30K Apr 29, 2022 Common Stock 5K $37.46 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 70% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime.
F2 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.